Vaccination in the framework of clinical trials of the Russian vaccine against COVID-19 “Sputnik V” has been suspended, reports the Reuters…
It is noted that the reason for the suspension of clinical trials was allegedly a shortage of the drug, although earlier the head of NITsEM, Alexander Gintsburg, said that the tests of “Sputnik V” continued and “there is no shortage of vaccine.”
A spokesman for Crocus Medical, which helps conduct vaccine trials, told the agency that the demand for Sputnik V is “colossal” and there is not enough vaccine to cover it.
The tests are scheduled to resume on November 10.
Note, President Vladimir Zelensky announced the production of a Ukrainian vaccine from coronavirus infection. It has been developed for more than six months and is now being tested.
It was also reported that the Ukrainian COVID-19 treatment protocol “Remdesivir” (trade name Veklury) was incorporated back in March. At the beginning of the epidemic, it was produced only by the American pharmaceutical company Gilead Sciences, Inc., later transferred production licenses for 127 countries of the Asian market to nine companies in India, Egypt, and Pakistan. However, the expediency of the purchase remains in question. On October 15, WHO released a study that noted that Remdesivir does not affect mortality, or reduces the need for ventilation. Some experts argue that the drug can only be effective in the early stages.
Remdesivir became the first drug in the USA, which was approved by the US Food and Drug Administration for the treatment of patients with coronavirus infection COVID-19. Remdesivir has already shown itself to be positive in the fight against Ebola.